Mirati Therapeutics Inc

-0.17 (-0.24%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)3.87B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.01 Million
Adjusted EPS-$3.45
See more estimates
10-Day MA$71.52
50-Day MA$76.55
200-Day MA$83.85
See more pivots

Mirati Therapeutics Inc Stock, NASDAQ:MRTX

3545 Cray Court, Suite 200, San Diego, California 92121
United States of America
Phone: +1.858.332.3410
Number of Employees: 418


Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.